Is NCT06858397 recruiting in Fairfax, VA?

Yes, NCT06858397 is currently recruiting participants at its Fairfax, VA location. This fabry disease clinical trial is actively enrolling qualified participants.

How do I join the fabry disease clinical trial in Fairfax?

To join this clinical trial in Fairfax, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Fairfax clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Fabry Disease Clinical Trial in Fairfax, VA

Who Can Participate

Inclusion Criteria

Participants must be ≥ 18 years of age or age considered as adult in the respective country at the time of signing the informed consent.

Documented diagnosis of FD with clinical symptoms.

Females: historical genetic test results based on identification of pathogenic or likely pathogenic GLA variant of FD.

Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal (LLN in plasma=3.2 nmol/hr/mL, LLN in leucocytes=32 nmol/hr/mg/protein).

Patients who are naive or have not received FD therapy including investigational therapy for FD within the past 6 months prior to screening and have negative ADA testing at screening.

Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Plasma lyso-Gb3 levels greater than 1.5 times the upper limit of normal (ULN).

Male participants:

Male participants are eligible to participate if they agree to the following during the study treatment period:

Refrain from donating sperm, PLUS either:

Be abstinent from heterosexual intercourse with a woman of childbearing potential (WOCBP) as their preferred and usual lifestyle (abstinent on a longterm and persistent basis) and agree to remain abstinent, OR

Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person,

In addition to male condom, use of highly effective method of contraception may be considered in WOCBP partners of male participants.

Female participants:

Female participants are eligible to participate if they are not pregnant or breastfeeding, and at least 1 of the following conditions applies:

Is not a WOCBP, OR

Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year), preferably with low user dependency, starting at least one menstrual cycle before first study drug administration and continuing for at least 30 days after the end of systemic exposure of the study drug and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study drug.

A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study drug.

If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Women whose postmenopausal status is recent, may perform additional follicle stimulating hormone (FSH) testing. Informed Consent

Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria

Women who are pregnant, planning to become pregnant during the study, or are breast feeding.

History of dialysis or renal transplantation.

CKD stage ≥ 3.

History of acute kidney injury within 12 months prior to screening, including specific kidney diseases (eg, acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (eg, ischemia, toxic injury); as well as extrarenal pathology (eg, prerenal azotemia, and acute postrenal obstructive nephropathy).

Urine protein to creatinine ratio (UPCR) \> 0.5 g/g and not treated with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).

Known history of hypersensitivity to any ingredient in the investigational product and to Gadolinium contrast agent that is not managed by the use of premedication.

Cardiovascular event (myocardial infarction, unstable angina) within 6 months before screening.

Congestive heart failure New York Heart Association (NYHA) Class IV

History of stroke.

Pacemaker or other contraindication for magnetic resonance imaging (MRI) scanning.

Angiotensin converting enzyme inhibitor or ARB therapy initiated or dose changed in the 4 weeks prior to screening.

Patients who received investigational gene therapy for FD.

Participation in other studies involving study drugs within 4 weeks prior to study entry and/or during study participation.

Participating in interventional study or using compassionate access product for FD. Participants who have participated in interventional trials for conditions not related to FD should be enrolled after the adequate wash out period is over, which is 5 half-lives or 30 days whichever is longer.

Presence of human immunodeficiency virus (HIV) and/or active (acute or chronic) hepatitis B and/or Hepatitis C infections.

Presence of any medical, emotional, behavioral, or psychological condition that, in the judgment of the Investigator and/or Medical Monitor, would interfere with the participant's compliance with the requirements of the study.

Participants who may have history of deliberate self-harm or suicidal ideation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairfax?

Yes, this clinical trial (NCT06858397) has an active research site in Fairfax, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Fabry Disease Treatment Options in Fairfax, VA

If you're searching for fabry disease treatment options in Fairfax, VA, this clinical trial (NCT06858397) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairfax research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced fabry disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all fabry disease clinical trials near you to find additional studies recruiting in your area.

Fabry Disease Clinical Trial in Fairfax, VA

Expert Care in Fairfax

IRB Approved

No-Cost Care

Apply for This Fairfax Location

Why Participate?

Simple Process

About This Fabry Disease Study in Fairfax